Urethra cancer
MONDO:0004192A malignant neoplasm involving the urethra
Also known as: cancer of urethra, malignant neoplasm of the urethra, malignant neoplasm of urethra, malignant tumor of the urethra, malignant tumor of urethra, malignant tumour of the urethra, malignant urethra neoplasm, malignant urethra tumor
2785 clinical trials for this condition and its sub-types, 18 tagged with Urethra cancer itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Urethra cancer
-
Carcinoma of urethra 2 trials · 21 incl. sub-types
5 sub-types
- Urethra transitional cell carcinoma 17 trials Sub-types →
- Urethra adenocarcinoma 1 trial · 2 incl. sub-types Sub-types →
- Urethra squamous cell carcinoma 2 trials Sub-types →
- Littre gland carcinoma 0 trials Sub-types →
- Carcinoma in situ of urethra 0 trials
-
Anterior urethra cancer 0 trials
-
Female urethral cancer 0 trials
-
Male urethral cancer 0 trials
4 sub-types
- Littre gland carcinoma 0 trials Sub-types →
- Bulbomembranous urethral cancer 0 trials
- Penile urethral cancer 0 trials
- Prostatic urethral cancer 0 trials Sub-types →
-
Posterior urethra cancer 0 trials
Most studied deeper sub-types
-
New hope for Hard-to-Treat cancers: enhertu studied in 20+ tumor types
Disease control Recruiting nowThis study is testing the drug T-DXd (Enhertu) in 100 adults with advanced HER2-positive solid tumors who have already tried other treatments and have no good options left. The goal is to see how well the drug works in real-world settings, including how many patients respond and …
Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Can a targeted antibody-drug combo tackle rare bladder cancers?
Disease control Recruiting nowThis phase II trial is testing whether combining enfortumab vedotin—a drug that delivers a cancer-killing agent directly to tumor cells—with the immunotherapy pembrolizumab can shrink tumors in people with locally advanced or metastatic bladder cancer of variant histology. These …
Phase 2 • Sponsor: Emory University • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New imaging agent could reveal which cancers respond to immunotherapy
Diagnosis Recruiting nowThis phase I/II trial tests a radioactive tracer called 64Cu-GRIP B, which targets granzyme B—a substance released by immune cells. By using PET scans, researchers hope to see immune activity in tumors and predict whether immunotherapy will work. The study involves about 91 adult…
Phase 1/2 • Sponsor: Rahul Aggarwal • Aim: Diagnosis
Last updated Jun 27, 2026 11:03 UTC
-
Massive cancer database aims to unlock secrets of the disease
Knowledge-focused Recruiting nowThis study is building a huge registry of information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. Researchers will use this resource to study what causes cancer and how to better prevent, detect, and treat it. The re…
Sponsor: University of Nebraska • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC